Takeda

We follow the science, to unlock innovation and pursue sustainable answers. We are guided by our commitment to patients, our people and the planet. Our vision is to deliver life-transforming treatments to those in need. We are steadfast in our purpose for better health for people and a brighter future for the world.

Partnerships play a vital role in developing and delivering life-transforming treatments for patients worldwide. Today, we’re celebrating 25 years of strong, collaborative partnership with Zydus Group at our manufacturing site in Vashi, India. Specializing in the production of high-quality active pharmaceutical ingredients (APIs) and intermediates, the Vashi site plays an important role in helping deliver life-transforming treatments to patients. To celebrate this milestone, we honored our dedicated employees with a festive event embracing traditional Indian customs. The occasion not only recognized their invaluable contributions but also reaffirmed our commitment to patients and safety, quality, and environmental sustainability as we look toward the future.  #Manufacturing #Pharma #Collaboration #Sustainability

Start the new year off strong and join our team! Our mission of creating better health and a brighter future is ambitious, and our people are the greatest promise for delivering on it. Let’s make history and change futures, together: https://lnkd.in/eY7snQ8U #NewJob #Hiring #MakeHistoryChangeFutures #TeamTakeda

Today, we shared our financial results for the third quarter of FY2024 and we now expect revenue, Core Operating Profit and Core Operating Profit margin growth this year. Our Growth & Launch Product portfolio, which represents 47% of our total revenue, is delivering strong momentum. Our late-stage pipeline including three Phase 3 programs with planned readouts in calendar year 2025 is advancing. Learn more about our results, outlook, pipeline progress and how we are maximizing our existing portfolio to treat more patients, including information about forward-looking statements and non-IFRS metrics, here: here: https://lnkd.in/gqqx9UBF Sign up for our investor newsletter to stay updated on our milestones and commitments to patients, our people, and the planet: https://lnkd.in/g_qR7cX5

Today we announced that, after a multi-year succession process, Takeda’s Board of Directors has made a unanimous decision to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, president and CEO, when Christophe retires from Takeda in June 2026.    Now is the right time to prepare for a CEO transition given our competitive growth outlook and new product launches expected from the second half of 2026 onwards.    More details, including information about forward-looking statements, on Takeda.com. https://lnkd.in/dGZC-KsD  

Diagnosing #CeliacDisease (CeD) can be complex because symptoms often overlap with other conditions, requiring additional testing for accuracy. Discover Bill’s journey with CeD – from the challenges he faced before diagnosis to how he now manages daily life: https://lnkd.in/egdRZ7Jt

El diagnóstico de la enfermedad de Fabry sólo es posible con un estudio genético. Reconocer los síntomas a tiempo es crucial para disminuir su progresión. #enfermedaddefabry #fabry #tratamientofabry #enfermedadesraras #diagnosticofabry

Discover how the tyrosine kinase 2, or TYK2, pathway contributes to inflammation – a hallmark of immune-mediated inflammatory disease like psoriasis, psoriatic arthritis and inflammatory bowel disease. Watch our 2-minute video to learn about the “immune orchestra” and how we are advancing research to improve our understanding of TYK2 biology: https://lnkd.in/eSEx_Qvv

Mark your calendar to join our leaders across Data, Digital & Technology (DD&T) and Engineering on January 28 at 10 am EST/4 pm CET for a LinkedIn Live.    Explore the future of digital transformation in pharmaceutical manufacturing, and discover how your digital skills can enhance efficiency and drive value through:   - Next level IT/OT Partnership  - Digital Manufacturing    - Paperless Transformation & Predictive Maintenance Be part of the conversation shaping the future of pharma. #MakeHistoryChangeFutures #TeamTakeda  

Alpha-1 antitrypsin deficiency (AATD) can cause chronic #LiverDisease, but it is often overlooked or misdiagnosed because its symptoms vary (also known as a heterogenous presentation). Through evidence generation, we are helping to highlight the need for early screening and non-invasive testing, to ultimately support the timely and accurate diagnosis of patients. Learn more about our focus in gastrointestinal and inflammatory diseases: https://lnkd.in/e-Me3WrB